Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Non-ad5 adenoviral vectors and methods and uses related thereto

An adenovirus and human adenovirus technology, applied in the field of medicine, can solve the problem of lack of a reasonable basis for tumor selectivity, and achieve the effect of improving cancer treatment and reducing side effects

Inactive Publication Date: 2012-01-18
ONCOS THERAPEUTICS
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, based on the method used to develop ColoAd1, ColoAd1 lacks a plausible basis for tumor selectivity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-ad5 adenoviral vectors and methods and uses related thereto
  • Non-ad5 adenoviral vectors and methods and uses related thereto
  • Non-ad5 adenoviral vectors and methods and uses related thereto

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0101] cell culture

[0102] 293 cells were purchased from Microbix (Toronto, Canada). 293-2v6-11 cells contain a ponasteron-inducible E4orf6 domain (Mohammadi E.S. et al. 2004, Nucleic Acids Res 32:2652-2659). 911-1c11 cells were maintained in 1 mg / ml of G418 (Sirena, D. et al. 2005, Virology 343:283-298). The SKOV3.ip1 ovarian adenocarcinoma cell line was obtained from Dr. Price (M.D. Anderson Cancer Center, Houston, TX). The ovarian adenocarcinoma cell line SKOV3-luc expressing firefly luciferin was kindly provided by Dr. Negrin (Stanford Medical School, Stanford, CA). The highly metastatic, hormone-resistant subline of prostate cancer, PC-3MM2, was a kind gift of Isaiah J. Findler (MD Anderson Cancer Center, Houston, TX). The highly lympho-metastatic subline LNM35 / EGFP of human lung large cell carcinoma was provided by Takashi Takahashi (The Honda Research Institute, Japan). Human umbilical vein endothelial cells known as HUVECs were purchased from Lonza (Basel, Switze...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the field of medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic human adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to a method of producing an adenoviral vector.

Description

field of invention [0001] The present invention relates to the field of medicine. In particular, the invention relates to cancer therapy. More particularly, the present invention relates to oncolytic human adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The invention also relates to the use of said vector in the manufacture of a medicament for the treatment of cancer in a subject, and to methods of treating cancer in a subject. Furthermore, the present invention relates to methods of producing adenoviral vectors. Background of the invention [0002] Cancer can be treated with surgery, hormonal therapy, chemotherapy, and / or radiation therapy, but in many cases, cancers that are often characterized as advanced are not curable with current therapies. Therefore, new methods of targeting cancer cells, such as gene therapy, are needed. [0003] Gene transfer techniques have been intensively tested over the past 20 years. The goal of cance...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/861A61K35/76A61K35/761
CPCA61K35/761C12N2830/60C12N2710/10322C12N2840/203C12N15/86C12N2710/10332A61K48/00C12N2830/85A61K38/193A61K38/177C12N2830/008C12N7/00C12N2710/10343C12N2710/10371C12N2710/10345A61P19/08A61P35/00A61P35/02C12N5/10C12N15/861A61K35/76A61K31/7088
Inventor O·海明基G·鲍尔施密茨V·切鲁洛S·佩索宁A·海明基
Owner ONCOS THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com